News | November 14, 2022
Aurobindo Pharma Q2 FY23 revenue down 3.4%
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
Kauliv provides reusable and disposable pen2 device options to cater to the global market demand.
First and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe
Viehbacher brings extensive international experience in large pharmaceutical and entrepreneurial biotech companies
PIKA COVID-19 vaccine is currently in Phase 3, multi-country, multi-center clinical trial conducted at Southeast Asian and Middle East countries.
Dr. Mandaviya agreed to host the Stop TB Partnership’s 36th Board meeting on March 25-26, 2023 in Varanasi
ASG is accelerating its doctor-led mission to enhance the quality of care, deliver eye care for all, and improve quality of life across India.
Revenue is up 23% whereas Profit After Tax expands 29% for the company
API platform to comprise of RA Chem Pharma, ZCL Chemicals and Avra Laboratories
The participants discussed the latest developments under ABDM that shall enable true interoperability in the health sector and how effective adoption of ABDM can pave the way towards Universal Health Coverage
Subscribe To Our Newsletter & Stay Updated
